Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays

Clinical and Diagnostic Laboratory Immunology

Volumn 4, Issue 2, 1997, Pages 156-167

  Maslanka, Susan E ^a,k   Gheesling, Linda L ^a   Libutti, Daniel E ^a   Donaldson, Kimberley B J ^a   Harakeh, Hani S ^a   Dykes, Janet K ^a   Arhin, Francis F ^b   Devi, Sarvamangala J N ^c   Frasch, Carl E ^c   Huang, Jay C ^d   Kriz Kuzemenska, Paula ^e   Lemmon, Robert D ^f   Lorange, Manon ^g   Peeters, Carla C A M ^h   Quataert, Sally ⁱ   Tai, Joseph Y ^j   Carlone, George M ^a   Mills, Elaine L ^b   Ashton, Fraser E ^d   Diepevaen, Jacob ^d   Bielecki, Joanna ^d   Bybel, Michael ^f   Cloutier, Martin ^g   Poolman, Jan T ^h   more..

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d LAB CENTRE FOR DISEASE CONTROL   (Canada)

^e NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^f Connaught Laboratories Inc ^*  (United States)

^g Quebec National Public Health Institute   (Canada)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁱ Lederle Praxis Biologicals   (United States)

^j North American Vaccine Inc   (United States)

^k CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNIZATION; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PRIORITY JOURNAL; STANDARDIZATION;

EID: 0342891343     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.4.2.156-167.1997     Document Type: Article

References (40)

1. Anderson, E. L., T. Bowers, C. M. Mink, D. J. Kennedy, R. B. Belshe, H. Harakey, L. Pais, P. Holder, and G. M. Carlone. 1994. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62:3391-3395.
2. Cadoz, M., J. Armand, F. Arminjon, R. Gire, and C. Lafaix. 1984. Tetravalent (A,C,Y,W 135) meningococcal vaccine in children: immunogenicity and safety. Vaccine 3:340-342.
3. Carlone, G. M., C. E. Frasch, G. R. Siber, S. Quataert, L. L. Gheesling, S. H. Turner, B. D. Plikaytis, L. O. Helsel, W. E. DeWitt, W. F. Bibb, B. Swaminathan, G. Arakere, C. Thompson, D. Phipps, D. Madore, and C. V. Broome. 1992. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 30:154-159.
4. Craven, D. E., K. T. Shen, and C. E. Frasch. 1982. Natural bactericidal activity of human serum against Neisseria meningitidis isolates of different serogroups and serotypes. Infect. Immun. 37:132-137.
5. Davis, S. D., and R. J. Wedgwood. 1965. Kinetics of the bactericidal action of normal serum on gram-negative bacteria. J. Immunol. 95:75-79.
6. Frasch, C. E., and J. D. Robbins. 1978. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J. Exp. Med. 147:629-644.
7. Gheesling, L. L., G. M. Carlone, L. B. Pais, P. F. Holder, S. E. Maslanka, B. D. Plikaytis, M. Achtman, P. Densen, C. E. Frasch, H. Käyhty, J. P. Mays, L. Nencioni, C. Peeters, D. C. Phipps, J. T. Poolman, E. Rosenqvist, G. R. Siber, B. Thiesen, J. Tai, C. M. Thompson, P. P. Vella, and J. D. Wenger. 1994. Multicenter comparison of Neisseria meningitidis serogroup C anticapsular polysaccharide antibody levels measured by a standardized enzymelinked immunosorbent assay. J. Clin. Microbiol. 32:1475-1482.
8. Gold, R., and F. A. Wyle. 1970. New classification of Neisseria meningitidis by means of bactericidal reactions. Infect. Immun. 1:479-484.
9. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
10. Gotschlich, E. C., I. Goldschneider, and M. S. Artenstein. 1969. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 129: 1367-1384.
11. Gotschlich, E. C., T. Y. Liu, and M. S. Artenstein. 1969. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 129:1349-1365.
12. Griffiss, J. M., and D. K. Goroff. 1983. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J. Immunol. 130:2882-2885.
13. Heist, G. D., S. Solis-Cohen, and M. Solis-Cohen. 1922. A study of the virulence of meningococci for man and of human susceptibility to meningococcic infection. J. Immunol. 7:1-33.
14. Holder, P. K., S. E. Maslanka, L. B. Pais, J. Dykes, B. D. Plikaytis, and G. M. Carlone. 1995. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentration to the new standard reference serum CDC1992. Clin. Diagn. Lab. Immunol. 2:132-137.
15. Kasper, D. L., J. L. Winkelhake, B. L. Brandt, and M. S. Artenstein. 1973. Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J. Infect. Dis. 127:378-387.
16. King, W. J., N. E. Macdonald, G. Wells, J. Huang, U. Allen, F. Chan, W. Ferris, F. Diaz-Mitoma, and F. Ashton. 1996. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J. Pediatr. 128:196-202.
17. Kolmer, J. A., I. Toyama, and T. Matsunami. 1918. The influence of active normal serum (complement) upon meningococci. I. The opsonic activity of fresh normal serum alone and in combination with antimeningitis serum for meningococci. J. Immunol. 3:157-175.
18. Leach, A., P. A. Twumasi, S. Kumah, W. S. Banya, S. Jaffar, B. D. Forrest, D. M. Granoff, D. E. LiButti, G. M. Carlone, L. B. Pais, C. V. Broome, and B. M. Greenwood. 1997. Induction of immunologic memory in Gambian children by vaccination with a group A plus C meningococcal polysaccharideprotein conjugate vaccine. J. Infect. Dis. 175:200-204.
19. Mandrell, R. E., F. H. Azmi, and D. M. Granoff. 1995. Complement-mediated bactericidal activity of human antibodies to poly α2→8 N-acetyl neuraminic acid, the capsular polysaccharide of Neisseria meningiditis serogroup B. J. Infect. Dis. 172:1279-1289.
20. Milagres, L. G., S. R. Ramos, C. T. Sacchi, C. E. A. Melles, V. S. D. Vieira, H. Sato, G. S. Brito, J. C. Moraes, and C. E. Frasch. 1994. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:4419-4424.
21. Mitchell, L. A., J. J. Ochnio, C. Glover, A. Y. Lee, M. K. L. Ho, and A. Bell. 1996. Analysis of meningococcal serogroup C specific antibody levels in British Columbian children and adolescents. J. Infect. Dis. 173:1009-1013.
22. Moran, E. E., B. L. Brandt, and W. D. Zollinger. 1994. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:5290-5295.
23. Nicholson, A., and I. H. Lepow. 1979. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 205: 298-299.
24. Occhionero, M., G. Usai, M. Di Martino, S. Le Moli, T. Stroffolini, and P. Mastrantonio. 1990. Serum antibodies to capsular polysaccharide vaccine of group A and C Neisseria meningitidis in military recruits in Italy. Immunol. Clin. 9:159-164.
25. Peltola, H., P. H. Mäkelä, H. Käyhty, H. Jousimies, E. Herva, K. Hällström, A. Sivonen, O. Renkonen, O. Pettay, V. Karanka, P. Ahvonen, and S. Sarna. 1977. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 297:686-691.
26. Plikaytis, B. D., P. F. Holder, L. B. Pais, S. E. Maslanka, L. L. Gheesling, and G. M. Carlone. 1994. Determination of parallelism and nonparallelism in bioassay dilution curves. J. Clin. Microbiol. 32:2441-2447.
27. Reingold, A. L., A. W. Hightower, G. A. Bolan, E. E. Jones, H. Tiendrebeogo, C. V. Broome, G. W. Ajello, C. Adamsbaum, C. Phillips, and A. Yada. 1985. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet ii:114-118.
28. Ross, S. C., H. M. Berberich, and P. Densen. 1985. Natural serum bactericidal activity against Neisseria meningitidis isolates from disseminated infections in normal and complement-deficient hosts. J. Infect. Dis. 152:1332-1335.
29. Söderström, C., J. H. Braconier, D. Daniclsson, and A. G. Sjöholm. 1987. Bactericidal activity for Neisseria meningitidis in properdin-deficient sera. J. Infect. Dis. 156:107-112.
30. 29a.Tappero, J. (Centers for Disease Control and Prevention). Personal communication.
31. Taylor, P. W. 1978. The effect of the growth environment on the serum sensitivity of some urinary Escherichia coli strains. FEMS Microbiol. Lett. 3:119-122.
32. Thomas, L., and J. H. Dingle. 1943. Investigations of meningococcal infection. III. The bactericidal action of normal and immune sera for the meningococcus. J. Clin. Invest. 22:375-385.
33. Wedege, E., E. A. Høiby, E. Rosenqvist, and L. O. Frøholm. 1990. Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dotblotting and ELISA. J. Med. Microbiol. 31:195-201.
34. Weibel, R. E., V. M. Villarejos, P. P. Vella, A. F. Woodhour, A. A. Mclean, and M. R. Hilleman. 1976. Clinical and laboratory investigation of monovalent and combined meningococcal polysaccharide vaccines, group A and C. Proc. Soc. Exp. Biol. Med. 153:436-440.
35. Wong, K. H., O. Barrera, A. Sutton, F. May, D. H. Hochstein, J. D. Robbins, P. D. Parkman, and E. B. Seligmann, Jr. 1977. Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J. Biol. Stand. 5:197-215.
36. World Health Organization. 1976. Requirements for meningococcal polysaccharide vaccine (requirements for biological substances no. 23). W. H. O. Tech. Rep. Ser. 594:72-73.
37. Zangwill, K. M., R. W. Stout, G. M. Carlone, L. Pais, H. Harakeh, S. Mitchell, W. H. Wolfe, V. Blackwood, B. D. Plikaytis, and J. D. Wenger. 1994. Duration of antibody response after meningococcal polysaccharide vaccination in U.S. Air Force personnel. J. Infect. Dis. 169:847-852.
38. Zar, J. R. 1984. Biostatistic analysis, 2nd ed., p. 263-266, 306-311. Prentice-Hall, Inc., Englewood Cliffs, N.J.
39. Zollinger, W. D., J. Boslego, L. O. Frøholm, J. S. Ray, E. E. Moran, and B. L. Brandt. 1987. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie Leeuwenhoek 53:403-411.
40. Zollinger, W. D., and R. E. Mandrell. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264.